Payers Must Brace For Coming Wave Of Cell And Gene Therapies
Executive Summary
One regenerative medicine for an ultra-rare disease may have a small impact, but payers will be flooded with dozens of new cell and gene therapies over the next few years. Enzyvant, Novartis and Spark share how they are positioning their complex products.
You may also be interested in...
Kite CEO Christi Shaw On How Gilead Plans To Stay On Top In Cell Therapy
Shaw cites manufacturing speed and success as competitive edges. The Gilead subsidiary unveiled data at ASCO positioning Tecartus, its second CAR-T therapy, to add B-cell acute lymphoblastic leukemia to label.
Generic Industry’s Future May Include A Role In The Gene Therapy Space
Trade association’s CEO says a new strategic planning initiative will consider among other things how gene therapy could fit into the generic industry business model.
Sumitovant Keeping Sumitomo Dainippon-Acquired Roivant Companies On Track
Scrip spoke with Sumitovant CEO Myrtle Potter about short- and long-term goals for the portfolio of five companies, including Myovant, Urovant and Enzyvant with potential near-term approvals.